GKOS

Glaukos Corporation

Oct 21 • 09:41AM ET

76.44

-3.03 -3.82 %

Healthcare • Medical Devices • USA • NYSE

Peers: ALGN ZBH BSX EW ISRG MDT SYK COO BAX HOLX

| Held by: IJR VTI IWM VB VBK VXF SPSM IWO IJT IHI

Index	RUT	P/E	-	EPS (ttm)	-1.66	Insider Own	3.77%	Shs Outstand	57.25M	Perf Week	-10.41%
Market Cap	4.38B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-0.26%	Shs Float	55.22M	Perf Month	-9.67%
Enterprise Value	4.21B	PEG	-	EPS next Q	-0.26	Inst Own	107.55%	Short Float	5.71%	Perf Quarter	-20.38%
Income	-92.79M	P/S	10.13	EPS this Y	51.44%	Inst Trans	0.91%	Short Ratio	3.31	Perf Half Y	-14.81%
Sales	432.95M	P/B	5.72	EPS next Y	98.64%	ROA	-9.73%	Short Interest	3.15M	Perf YTD	-49.02%
Book/sh	13.36	P/C	15.95	EPS next 5Y	-	ROE	-12.98%	52W High	163.71 -53.31%	Perf Year	-40.86%
Cash/sh	4.79	P/FCF	-	EPS past 3/5Y	-37.46% -	ROIC	-10.66%	52W Low	75.36 1.43%	Perf 3Y	42.13%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	9.26% 10.10%	Gross Margin	76.34%	Volatility	7.25% 4.41%	Perf 5Y	40.25%
Dividend TTM	-	EV/Sales	9.73	EPS Y/Y TTM	48.19%	Oper. Margin	-22.33%	ATR (14)	4.02	Perf 10Y	248.55%
Dividend Ex-Date	-	Quick Ratio	4.69	Sales Y/Y TTM	26.70%	Profit Margin	-21.43%	RSI (14)	35.49	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	5.51	EPS Q/Q	65.52%	SMA20	-8.59%	Beta	0.81	Target Price	117.50
Payout	-	Debt/Eq	0.14	Sales Q/Q	29.71%	SMA50	-12.33%	Rel Volume	2.65	Prev Close	79.47
Employees	995	LT Debt/Eq	0.14	Earnings	Oct 29 AMC	SMA200	-26.55%	Avg Volume	952.88K	Price	76.44
IPO	Jun 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.16% 7.44%	Trades		Volume	193,697	Change	-3.82%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-25	Initiated	Goldman	Buy	$103
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$86
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform	$140 → $200
Dec-11-24	Upgrade	Citigroup	Neutral → Buy	$132 → $162
Dec-06-24	Initiated	UBS	Buy	$182
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$120
Jul-10-24	Downgrade	Citigroup	Buy → Neutral	$132
May-06-24	Upgrade	Jefferies	Hold → Buy	$84 → $125
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight	$66 → $91
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$65
Nov-28-23	Initiated	Truist	Buy	$88
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$75 → $83
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight	$55 → $80
Dec-22-22	Initiated	Mizuho	Neutral	$48
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral	$48 → $42
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$57
Oct-14-22	Resumed	Stephens	Overweight	$69
Oct-04-22	Initiated	Needham	Buy	$66
Jul-12-22	Upgrade	Stifel	Hold → Buy	$40 → $60
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform

Show Previous Ratings

Oct-20-25 07:00AM	Glaukos Announces FDA Approval of Epioxa (Business Wire) -8.83%
06:31AM	Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel (Insider Monkey)
Oct-14-25 07:00AM	Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-08-25 07:00AM	Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 (Business Wire)
Oct-01-25 11:01AM	Goldman Sachs initiates ophthalmology coverage: Buy Glaukos, sell Cooper (Investing.com)
04:05PM	Loading…
Sep-25-25 04:05PM	Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama (Business Wire)
Sep-18-25 10:40AM	Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa (Insider Monkey)
Sep-02-25 10:10AM	Glaukos Builds Dual Growth Engines Amid Market Headwinds (Zacks)
Aug-13-25 07:00AM	Glaukos Announces Participation in Wells Fargo Healthcare Conference (Business Wire)
Jul-31-25 01:27PM	GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised (Zacks) -8.46%
Jul-30-25 05:45PM	Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:43PM	Glaukos: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Second Quarter 2025 Financial Results (Business Wire)
Jul-29-25 09:30AM	Glaukos Corp (GKOS) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Jul-09-25 08:18AM	Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks (Zacks)
07:00AM	Loading…
07:00AM	Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30 (Business Wire)
Jul-08-25 08:00AM	FELIQS Appoints Gregory Kunst and Joe Zenkus to Board of Directors (Business Wire)
Jun-27-25 10:37AM	Glaukos gains EU certification for iStent infinite and other MIGS devices (Medical Device Network)
Jun-25-25 04:05PM	Glaukos Announces EU MDR Certification for iStent infinite and Other Leading MIGS Therapies (Business Wire)
08:55AM	NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record (PR Newswire)
07:00AM	Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell (Business Wire)
Jun-16-25 12:00PM	What Makes Glaukos (GKOS) a New Buy Stock (Zacks)
Jun-11-25 09:55AM	Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect? (Zacks)
May-21-25 07:17AM	Here's Why You Should Retain Glaukos Stock in Your Portfolio (Zacks)
May-13-25 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
May-12-25 08:13AM	Glaukos Corporation (GKOS) Fell as its iDose Results Fell Short of Expectations (Insider Monkey) +5.20%
May-07-25 04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-01-25 12:00PM	Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -11.36%
11:32AM	GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline (Zacks)
11:04AM	Q1 2025 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Loading…
03:17AM	Glaukos Corp (GKOS) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... (GuruFocus.com)
Apr-30-25 10:05PM	Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:22PM	Glaukos: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 01:10PM	ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates (Zacks)
11:30AM	Baron Health Care Fund Q1 2025 Top Contributors And Detractors (Seeking Alpha)
Apr-28-25 01:18PM	RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up (Zacks)
11:24AM	Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y (Zacks)
Apr-27-25 02:22PM	Baron Health Care Fund Q1 2025 Shareholder Letter (Seeking Alpha)
Apr-25-25 12:50PM	Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now (Zacks)
12:48PM	Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand (Zacks)
Apr-24-25 01:02PM	Here's Why You Should Add Veeva Stock to Your Portfolio Now (Zacks)
11:36AM	WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit (Zacks)
10:01AM	Earnings Preview: Mettler-Toledo (MTD) Q1 Earnings Expected to Decline (Zacks)
Apr-23-25 12:39PM	ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts (Zacks)
10:01AM	Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:00AM	Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
Apr-16-25 07:00AM	Glaukos Announces the Release of its 2024 Sustainability Report (Business Wire) -6.05%
Apr-10-25 09:04AM	Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength? (Zacks)
Apr-09-25 07:00AM	Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30 (Business Wire) +13.71%
Apr-08-25 09:41AM	What Makes Glaukos Corporation (GKOS) a Compelling Stock? (Insider Monkey)
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-06-25 08:48AM	Glaukos: Macro Environment And Limited Market Access Could Stunt Growth Plans (Seeking Alpha)
Apr-02-25 12:01AM	Lord Abbett Developing Growth Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 10:49AM	The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals (Zacks)
Mar-31-25 09:10AM	3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space (Zacks)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-27-25 11:15AM	Columbia Select Mid Cap Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 11:10AM	Columbia Acorn Fund Q4 2024 Commentary (SeekingAlpha)
Mar-11-25 07:00AM	RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire: A Next-Generation Visual Field Solution (Business Wire)
Mar-04-25 11:52PM	Is Glaukos Corporation (GKOS) the Best Medical Technology Stock to Buy According to Analysts? (Insider Monkey)
Feb-24-25 07:00AM	Glaukos Announces FDA Acceptance of NDA Submission for Epioxa (Business Wire)
Feb-21-25 07:47PM	Wingstop Stocks Dip Is an Opportunity, Analyst Says. Plus, Devon Energy, Cadence Design, and More. (Barrons.com) -20.01%
02:15AM	Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ... (GuruFocus.com)
Feb-20-25 05:40PM	Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:34PM	Glaukos: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
12:00PM	Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz (TipRanks)
08:54AM	What To Expect From Glaukos Corp (GKOS) Q4 2024 Earnings (GuruFocus.com)
Feb-17-25 09:16AM	What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings (Zacks)
Jan-23-25 07:00AM	Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20 (Business Wire)
Jan-14-25 04:05PM	Glaukos Announces Positive Clinical Updates for its iDose Sustained-Release Procedural Pharmaceutical Platform (Business Wire)
Jan-04-25 07:45AM	Glaukos price target raised to $157 from $149 at BTIG (TipRanks)
Dec-23-24 07:00AM	Glaukos Submits New Drug Application to U.S. FDA for Epioxa (Business Wire)
Dec-19-24 07:30AM	Glaukos price target raised to $185 from $152 at Truist (TipRanks)
Dec-17-24 07:00AM	Glaukos Announces Participation in the J.P. Morgan Healthcare Conference (Business Wire)
Dec-07-24 05:35AM	Glaukos initiated with a Buy at UBS (TipRanks)
Dec-02-24 02:29PM	Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos (Benzinga)
Nov-08-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Nov-06-24 06:30AM	Glaukos price target raised to $145 from $135 at Wells Fargo (TipRanks) +10.00%
Nov-05-24 11:30AM	Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
11:18AM	Q3 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Glaukos Corp (GKOS) Q3 2024 Earnings Call Highlights: Record Sales and Raised Guidance Amid ... (GuruFocus.com)
Nov-04-24 05:25PM	Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:25PM	Glaukos: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Glaukos Announces Third Quarter 2024 Financial Results (Business Wire)
Nov-01-24 09:01AM	Earnings To Watch: Glaukos Corp (GKOS) Reports Q3 2024 Result (GuruFocus.com)
Oct-28-24 10:01AM	Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-17-24 10:06AM	Glaukos eyes FDA approval for ocular therapy after Phase III win (Pharmaceutical Technology)
Oct-16-24 04:05PM	Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety (Business Wire)
Oct-14-24 07:00AM	Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting (Business Wire)
Oct-09-24 07:00AM	Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4 (Business Wire)
Sep-09-24 05:16AM	Heres Why Glaukos (GKOS) Appreciated in Q2 (Insider Monkey)
Sep-03-24 02:16AM	Better Than Expected Earnings Results Boosted Glaukos Corp (GKOS) in Q2 (Insider Monkey)
Aug-22-24 01:16PM	Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock? (Zacks)
Aug-16-24 07:00AM	Glaukos Announces Participation in Upcoming Investor Conferences (Business Wire)
Aug-02-24 07:00PM	Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:50AM	Should You Be Bullish on Glaukos Corporation (GKOS)? (Insider Monkey)
Aug-01-24 11:40AM	Q2 2024 Glaukos Corp Earnings Call (Thomson Reuters StreetEvents)

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Sep 22 '25	Sale	84.22	517	43,541	76,390	Sep 24 06:53 PM
Navratil Tomas	Officer	Sep 22 '25	Proposed Sale	84.22	517	43,541		Sep 22 04:36 PM
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Sep 11 '25	Sale	88.22	5,142	453,620	75,469	Sep 12 08:42 PM
Navratil Tomas	Officer	Sep 11 '25	Proposed Sale	88.22	5,142	453,608		Sep 11 04:38 PM
Hoffmeister David F	Director	Jun 11 '25	Option Exercise	32.00	25,000	800,000	31,918	Jun 13 07:43 PM
Thurman Alex R.	SVP & CHIEF FINANCIAL OFFICER	Mar 25 '25	Sale	106.84	1,520	162,399	53,431	Mar 27 07:14 PM
Thurman Alex R.	Officer	Mar 25 '25	Proposed Sale	106.84	1,520	162,402		Mar 25 04:23 PM
Foley Mark J	Director	Feb 26 '25	Option Exercise	29.26	40,000	1,170,350	74,936	Feb 28 05:57 PM
Foley Mark J	Director	Feb 26 '25	Sale	120.72	20,687	2,497,335	54,249	Feb 28 05:57 PM
Foley Mark J	Director	Feb 26 '25	Proposed Sale	120.72	20,687	2,497,263		Feb 26 03:57 PM
Navratil Tomas	CHIEF DEVELOPMENT OFFICER	Feb 14 '25	Sale	147.14	3,416	502,630	72,437	Feb 19 06:00 PM
Navratil Tomas	Officer	Feb 14 '25	Proposed Sale	147.14	3,416	502,630		Feb 14 10:13 AM
Gilliam Joseph E	PRESIDENT & COO	Dec 20 '24	Option Exercise	59.74	3,328	198,830	105,497	Dec 23 09:15 PM
Gilliam Joseph E	PRESIDENT & COO	Dec 20 '24	Sale	149.85	3,328	498,716	102,169	Dec 23 09:15 PM
Kliman Gilbert H	Director	Dec 20 '24	Option Exercise	32.00	10,000	320,000	42,336	Dec 23 07:53 PM
Kliman Gilbert H	Director	Dec 20 '24	Sale	150.28	10,000	1,502,800	32,336	Dec 23 07:53 PM
Gilliam Joseph E	Officer	Dec 20 '24	Proposed Sale	149.85	3,657	548,017		Dec 20 04:27 PM
Kliman Gilbert H	Director	Dec 20 '24	Proposed Sale	150.28	10,000	1,502,789		Dec 20 04:21 PM
Kliman Gilbert H	Director	Dec 11 '24	Option Exercise	32.00	2,000	64,000	34,336	Dec 13 07:50 PM
Kliman Gilbert H	Director	Dec 11 '24	Sale	144.01	2,000	288,020	32,336	Dec 13 07:50 PM
Kliman Gilbert H	Director	Dec 11 '24	Proposed Sale	144.01	2,000	288,015		Dec 11 12:32 PM
Gilliam Joseph E	PRESIDENT & COO	Oct 30 '24	Option Exercise	69.30	2,275	157,658	104,444	Nov 01 05:30 PM
Gilliam Joseph E	PRESIDENT & COO	Oct 30 '24	Sale	138.97	2,275	316,157	102,169	Nov 01 05:30 PM
Gilliam Joseph E	Officer	Oct 30 '24	Proposed Sale	138.97	2,500	347,421		Oct 30 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GKOS

Glaukos Corporation

Upgrade your FINVIZ experience